Research and Investment Prospect of Human Vaccine Industry in China, 2014-2018, mainly studies the market, competition pattern and segmentations of human vaccine industry in China and analyzes the industry chain, import & export and key enterprises of human vaccine in China. This report analyzes the business performances of 7 key enterprises, including Beijing Tiantan Biological Products Co., Ltd, ChongQing ZhiFei Biological Products Co., Ltd, Walvax Biotechnology Co., Ltd, Liaoning Chengda Co., Ltd (LCD) etc.
Browse key industry insights with market data tables & figures & charts from the report, "Human Vaccine" with table of contents @ http://www.radiantinsights.com/research/research-and-investment-prospect-of-human-vaccine-industry-in-china
As one of powerful vaccine manufacturing countries in world, China has 42 vaccine manufacturers with approval license. In 2013, the total of lot release quantity of vaccines was about 755 million doses, increasing by 0.53% over the 751 million doses in 2012. Vaccine manufacturers mainly consist of state-owned enterprises, private enterprises and foreign-funded enterprises in China. Seeing from the lot release quantity of vaccine in 2013, the state-owned enterprises still take the leading position in vaccine market, with market shares of 62%, followed by private enterprises and foreign-funded enterprises successively, with market shares of 33.77% and 4.23% respectively.
Most of market of typeⅠvaccines is still dominated by state-owned enterprises, including 6 largest institutes of China National Biotec-Group Company Limited and Changchun Keygen Biological Products Co., Ltd. Private enterprises take half of market shares of typeⅡvaccines, the representative enterprises include: ChongQing ZhiFei Biological Products Co., Ltd, and Walvax Biotechnology Co., Ltd etc. While the international enterprises have definite advantages in respects of high-end vaccines and multivalent vaccines, taking pneumococcal vaccines for instance, only one conjugate vaccine is available, say: Pneumococcal 7-Valent Conjugate Vaccine produced by Pfizer. Although, at present, several enterprises are conducting studies on pneumococcal conjugate vaccines, it is still long to launch on the market, with huge uncertainties.
Get PDF request sample @ http://www.radiantinsights.com/research/research-and-investment-prospect-of-human-vaccine-industry-in-china/request-sample
In 2014-2018, the average growth rate of vaccine in China will maintain at 16%-18%. The main driving factors include: implement of national vaccine immunization plan, increasing receptivity of vaccine by people, rising trend of initiative vaccination and increase of type Ⅱvaccines application etc. It can be expected that the market scale of vaccine will hit CNY 40.5 billion in 2018.
Browse other trending reports:-
In-depth Research and Forecast of Chinas Dietary Supplement (Health Food) Industry, 2014-2018 :- From the perspective of the production scale and distribution channels, China's dietary supplement industry is still in the earlier stage of the development of European and American markets. In the aspect of enterprise size, China's dietary supplement enterprises mainly are within CNY 50 million to CNY 500 million. Therefore large-sized enterprises are few and enterprises with economies of scale are also few. @ http://www.radiantinsights.com/research/in-depth-research-and-forecast-of-china-s-dietary-supplement-health-food-industry-2014-2018/request-sample
Media Contact
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist - USA
Email:Send Email
Phone: (415) 349-0054, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
State: California
Country: United States
Website: http://www.radiantinsights.com/
